{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Record vital signs.', 'Perform partial physical examination (see Section 7.4.7.1).', 'Collect samples for chemistry panel and hematology assessments.', 'Collect sample for glycosylated hemoglobin (HbA1c) assessment (subjects with', 'confirmed diabetes mellitus only).', 'Collect and review Subject Diary.', 'For OKZ 64 mg q2w treatment group only:', '- Allocate study treatment through the IWRS.', '- Perform training for study treatment preparation, storage, and administration', '- Administer study treatment.', 'Study treatment will be administered by the subject (or caregiver, if applicable) at', 'this visit, and the Investigator must observe this administration to ensure that', 'proper procedures are followed', 'Subjects will remain at the study site for at least 30 minutes after the injection to', 'be assessed for onset of any systemic injection reactions.', '5.4.1.3', 'Visit 3 (Week 28)', 'The following assessments will be conducted at Visit 3 (Week 28):', 'Assess AEs/SAEs and injection site reactions that have occurred since the previous', 'visit.', 'Record details of contraceptive history/status.', 'Record concomitant medications and concomitant non-drug therapies.', 'Record weight.', 'Record vital signs.', 'Perform partial physical examination.', 'Collect samples for chemistry panel and hematology assessments.', 'Perform urine pregnancy test for females of childbearing potential only.', 'Amendment 2: 06 March 2019', '61', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Collect and review Subject Diary.', 'Allocate study treatment through the IWRS.', '-', 'In addition to study treatment for Visit 3 (Week 28) administration, subjects will', 'receive 1 vial or 1 pre-filled syringe (PFS) of OKZ for each dose that is scheduled to', 'be administered prior to Visit 4 (Week 36).', 'Perform training for study treatment preparation, storage, and administration', '(OKZ 64 mg q4w treatment group only).', 'Administer study treatment.', '-', 'Study treatment will be administered by the subject (or caregiver, if applicable) at this', 'visit, and the Investigator must observe this administration to ensure that proper', 'procedures are followed (observation is obligatory for OKZ 64 mg q4w treatment', 'group only)', '- Subjects in the OKZ 64 mg q4w treatment group will remain at the study site for at', 'least 30 minutes after the injection to be assessed for onset of any systemic injection', 'reactions.', '5.4.1.4', 'Visit 4 (Week 36)', 'Starting at Visit 4 (Week 36) and then at all onsite visits until the end of the open-label', 'Treatment Period, all subjects will be assessed for response to treatment, with nonresponders', 'defined as subjects who do not improve by at least 20% in SJC and TJC (66-68 joint', 'assessment) from the Core Baseline assessment. Investigators will be requested to review', 'carefully the response status at these time points and make appropriate actions based on local', 'guidelines regarding management of the subjects, including possible adjustments in', 'background therapy (see Section 6.13.3) or discontinuation of study treatment (see', 'Section 6.11).', 'The following assessments will be conducted at Visit 4 (Week 36):', 'Administer Patient Global Assessment of Disease Activity (VAS).', 'Administer Patient Assessment of Pain (VAS).', 'Administer HAQ-DI.', 'Administer SF-36, EQ-5D, FACIT-Fatigue, and WPS-RA.', 'Perform joint counts (Independent Joint Assessment).', 'Amendment 2: 06 March 2019', '62', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Assess AEs/SAEs and injection site reactions that have occurred since the previous', 'visit.', 'Administer Physician Global Assessment (VAS).', 'Record details of contraceptive history/status.', 'Record concomitant medications and concomitant non-drug therapies.', 'Administer TB risk questionnaire.', 'Record weight.', 'Record vital signs.', 'Perform partial physical examination.', 'Measure ESR.', 'Collect sample to measure CRP level.', 'Collect samples for chemistry panel and hematology assessments.', 'Collect sample for analysis of ADAs.', 'Perform urine pregnancy test for females of childbearing potential only.', 'Collect sample for urinalysis.', 'Collect and review Subject Diary.', 'Assess treatment compliance (see Section 6.7).', '-', 'Subjects who received vials must return all used/unused vials to the study site.', '- Subjects who received PFS must return carton of all used/unused PFS to the study', 'site.', 'Allocate study treatment through the IWRS.', '- In addition to study treatment for Visit 4 (Week 36) administration, subjects will', 'receive 1 vial or 1 PFS of OKZ for each dose that is scheduled to be administered', 'prior to Visit 5 (Week 44).', 'Administer study treatment.', 'Amendment 2: 06 March 2019', '63', 'Confidential']\n\n###\n\n", "completion": "END"}